Tenaya Therapeutics | IPO Presentation Deck

Slide schematic 8/8

image 2/2 list 3/3 table 1/1 title 2/2

Components 8

illustration photo bullet bullet bullet kpi action-title headline

Tools 1

Problem Statement Canvas slide · 60%

Pathophysiology: Mutation in MYBPC3 disrupts contractile apparatus (sarcomere); Cardiomyocyte hypertrophy, disarray and fibrosis; Stiff heart muscle contributes to poor heart filling; Abnormal heart rhythms.

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 1

before-after-bridge 80%

Contrasts the disease state (before) with the therapeutic solution (after).

Find anything

The slide uses a split-screen layout to contrast the disease state (pathophysiology) with the therapeutic intervention (product concept).